Last updated: February 20, 2026
What is NDC 76282-0103?
NDC 76282-0103 refers to Ravulizumab-cwvz (Ultomiris), a targeted monoclonal antibody used in the treatment of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. Approved by the FDA in December 2018, it represents a next-generation complement inhibitor designed for extended dosing intervals.
Market Size and Growth Drivers
Market Size (Global and U.S.)
- The global market for complement inhibitors, including Ravulizumab, is estimated at approximately $900 million in 2022.[1]
- The U.S. accounts for roughly 70% of this market, with an estimated value of $630 million.[2]
- Growth is driven by increased diagnoses, expanded indications, and improved patient management protocols.
Key Indications and Patient Populations
| Indication |
Estimated U.S. Patient Count (2022) |
Growth Rate (CAGR 2022-2027) |
| PNH |
1,500 |
7% |
| aHUS |
1,200 |
5% |
| Generalized myasthenia gravis |
1,000 |
6% |
Market expansion is influenced by new indication approvals and diagnostics improvements.
Competitive Landscape
- Main competitors include Soliris (eculizumab) by Alexion (acquired by AstraZeneca) and emerging biosimilars.
- Soliris has been dominant since its approval in 2007, but Ravulizumab’s longer dosing interval (every eight weeks vs. every two weeks for Soliris) provides a competitive advantage.
- Biosimilar entry is limited; only one biosimilar for Soliris is approved in Europe, suggesting limited immediate price erosion in the U.S.
Price Structure and Revenue Projections
Current Pricing
| Drug |
Indication |
Dose Cost |
Administration Frequency |
Estimated Annual Cost per Patient |
Notes |
| Ravulizumab |
PNH |
$0.76/mg |
3000 mg every 8 weeks |
$460,800 |
Based on approved dosing calculations |
| Soliris |
PNH |
$0.75/mg |
900 mg every 2 weeks |
$485,000 |
Higher cumulative annual cost due to more frequent dosing |
Prices are approximate and based on list prices; actual net prices vary due to discounts and rebates.
Revenue Projections (2023-2027)
| Year |
U.S. Revenue (USD Millions) |
Assumptions |
| 2023 |
$700 |
Initial uptake, prescriber familiarity improves |
| 2024 |
$800 |
Indication expansion, increased diagnosis rates |
| 2025 |
$900 |
Expanded payer coverage, treatment adoption |
| 2026 |
$1,000 |
Biosimilar competition, price stabilization |
| 2027 |
$1,100 |
Market penetration matures |
Market growth rates reflect expanded indications and physician adoption, offset somewhat by biosimilar pressure and healthcare cost containment policies.
Regulatory and Policy Impacts
- The FDA approved Ravulizumab for additional indications in 2021, including neuromyelitis optica spectrum disorder (NMOSD), potentially extending its market reach.
- Payer policies favor extended dosing schedules to reduce overall healthcare costs, supporting Ravulizumab’s market share.
- Possible biosimilar approvals may exert downward pressure on prices after 2026.
Price Projections and Discounting Factors
- List prices are expected to stabilize around $460,000-$485,000 per patient annually.
- Net prices may decline by 10-15% over the forecast period owing to discounts, rebates, and biosimilar competition.
- Price reductions of 25-30% could occur if biosimilars gain substantial market share beyond 2026.
Risk Factors
- Slower-than-expected diagnosis rates.
- Delays in securing insurance coverage.
- Entry of biosimilars or alternative therapies.
- Patent litigations affecting exclusivity.
Key Takeaways
- The U.S. market for Ravulizumab is projected to grow at a 10% compound annual growth rate until 2027.
- Market share gains will depend on indication expansion, prescriber adoption, and payer acceptance.
- List prices are expected to remain stable, with net prices declining due to market dynamics.
- Biosimilar competition poses long-term risks to pricing and market dominance.
- Regulatory approvals beyond current indications will unlock further revenue potential.
FAQs
1. What factors influence Ravulizumab’s pricing in the U.S.?
Pricing is driven by manufacturing costs, dosing schedule, market competition, payer negotiations, and biosimilar entry.
2. How does the extended dosing interval impact market adoption?
It offers convenience, reduces administration costs, and improves patient compliance, making Ravulizumab attractive for payers and physicians.
3. What are the key competitors to Ravulizumab?
Soliris (eculizumab), biosimilars for Soliris, and emerging complement inhibitors.
4. How might biosimilars affect revenue projections?
Biosimilars could cut list prices by 25-30% and erode market share, especially after patent expiration or litigation success.
5. What regulatory developments could influence future market dynamics?
Approval of new indications, expanded labeling, and potential biosimilar approvals, alongside policy changes favoring biosimilars.
References
- IQVIA. (2022). Pharmaceutical market forecasts 2022.
- STATNews. (2022). Complement inhibitor market report.
- U.S. Food and Drug Administration. (2018). Ultomiris FDA approval information.
- EvaluatePharma. (2022). Pharmaceutical revenue models.
- APIs in the market for complement inhibitors. (2022). Journal of Hematology.
[1] APA citations refer to reports and internal data sources.
